 In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite’s most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin’s lymphoma, known as diffuse large B cell lymphoma (DLBCL).The clinical data were presented at the 55th American Society of Hematology Annual Meeting.In March, the company announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's proposed therapy for DLBCL.